The human heart, a tireless pump, now benefits from equally tireless technology. Over the past six decades, cardiac implantable electronic devices (CIEDs) such as pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices have saved millions of lives. Yet their reliance on conventional batteries remains a persistent limitation. These power sources dictate device size, lifespan, and the need for repeated surgical replacement, each intervention carrying infection risks, patient anxiety, and substantial healthcare costs. Today, engineers and clinicians are rethinking energy supply at the microscopic level—not by making batteries bigger, but by making them unnecessary. This article examines the most promising innovations in power technologies for long-lasting cardiac implants, from harvesting the body's own kinetic and chemical energy to wireless recharging that eliminates the scalpel altogether.

Current Challenges in Cardiac Implant Power Sources

Standard lithium-iodine or lithium-carbon monofluoride batteries in pacemakers deliver 5–15 years of service, with ICD batteries lasting 5–7 years due to higher energy demands for shock delivery. While these chemistries are reliable, they are fundamentally constrained by energy density and the physical volume available inside the device. A larger battery means a larger implant, which may cause discomfort or complications. Moreover, the end-of-life phase often forces physicians to schedule elective battery replacements before critical failure—a surgery that, though routine, still carries a 1–4% complication rate including hematoma, infection, and lead damage. For patients with complex comorbidities, each additional procedure compounds risk.

The economic burden is also significant. In the United States alone, device replacement accounts for roughly 25% of all CIED procedures, costing the healthcare system hundreds of millions of dollars annually. Environmental concerns add another layer: discarded batteries contain toxic materials that require special disposal. These converging challenges have spurred a global search for power solutions that can outlast the patient's need for the device, or at least match the lifespan of modern leads and electronics—ideally beyond 20 years.

Emerging Power Technologies

Rather than simply refining battery chemistry, researchers are pursuing a paradigm shift: eliminate the battery as the sole energy source by converting ambient or physiological energy into electrical power. Three categories have emerged as front-runners: piezoelectric energy harvesting (mechanical-to-electrical conversion), wireless power transfer (remote recharging), and biofuel cells (biochemical conversion). Each offers distinct advantages and faces unique engineering hurdles. The most robust future systems will likely integrate two or more of these approaches to ensure continuous, redundant power delivery even under variable physiological conditions.

Piezoelectric Energy Harvesting

The heart's rhythmic contraction and relaxation generate mechanical stress that can be harvested using piezoelectric materials—crystals or polymers that produce an electric charge when deformed. Early prototypes placed thin films of polyvinylidene fluoride (PVDF) or lead zirconate titanate (PZT) onto pacemaker leads or directly onto the epicardium. These flexible patches can convert a fraction of the mechanical energy from each heartbeat into micro-watts of electricity. In a 2023 study published in Science Advances, researchers demonstrated a flexible piezoelectric device attached to a porcine heart that generated up to 0.5 μW per heartbeat—sufficient to power a low-duty-cycle pacemaker.

Challenges remain. The energy output depends on heart rate and contractility; a patient with bradycardia or heart failure produces less mechanical energy, reducing harvestable power. Additionally, the implanted material must remain compliant and biocompatible over decades without degrading. Researchers are exploring alternatives like lead-free potassium sodium niobate (KNN) to avoid toxicity concerns associated with lead-based piezoelectrics. Combined with advanced power management circuitry that stores harvested energy in a small capacitor or thin-film battery, these systems could extend device lifespan by 50% or more, reducing reliance on primary batteries.

For a comprehensive review of piezoelectric energy harvesting for biomedical implants, see this recent article in Science Advances.

Wireless Power Transfer

Wireless recharging offers an alternative: rather than harvesting energy from the body, energy is transmitted from an external unit through the skin to the implant. The most mature method uses inductive coupling between coils operating at low frequencies (100–500 kHz). This approach is already used in cochlear implants and some left ventricular assist devices. For cardiac implants, a patient could wear a charging vest or belt for 30 minutes daily, similar to a smartphone wireless charger, to maintain battery reserves indefinitely.

Inductive coupling, however, suffers from alignment sensitivity and limited depth penetration. Mid-field wireless power transfer—using higher frequencies (MHz range) and phased array techniques—improves efficiency at deeper depths. A team at Stanford University demonstrated a mid-field system capable of powering a 5 mm3 implant at depths of 10 cm with 80% efficiency. More recent work by WiTricity and others explores resonant coupling that adapts to movement and posture changes.

Safety is paramount. Excessive electromagnetic field exposure can heat tissue, so regulatory limits enforce strict specific absorption rate (SAR) thresholds. Advanced systems incorporate real-time temperature monitoring and automatic power reduction if heating exceeds safe limits. Despite these challenges, wireless charging has already entered clinical trials for pacemakers—a milestone that could make elective replacement surgeries obsolete within the next decade.

To learn more about clinical developments in wireless charging for medical implants, visit WiTricity's medical device page.

Biofuel Cells

Biofuel cells (BFCs) tap into the body's own chemistry. Enzymatic BFCs use glucose oxidase or laccase to oxidize glucose from interstitial fluid, producing electrons that flow through an external circuit. Since glucose is continuously supplied by the bloodstream, these cells offer the tantalizing prospect of a permanent power source—no recharging, no battery replacement. In proof-of-concept studies, glucose-powered fuel cells have generated up to 50 μW/cm2, enough to run low-power sensors but still below the requirements of a typical pacemaker (10–50 μW steady state, with higher bursts for sensing).

The biggest obstacles are stability and power density. Enzymes denature over weeks to months, losing catalytic activity. To address this, researchers are developing mediator molecules that protect the enzymes and extend operational life to over a year in vivo. Another approach uses abiotic catalysts such as platinum or carbon nanotubes, which are more durable but less selective. Additionally, the oxygen concentration at the cathode site can be inconsistent, leading to voltage fluctuations. Encapsulation strategies using permeable membranes allow glucose to reach the anode while keeping immune cells away, improving biocompatibility.

Despite these hurdles, significant progress has been made. In 2021, a team at the University of California, San Diego reported a glucose biofuel cell with a lifetime of 16 months in a rat model. If human lifetime versions can be achieved, BFCs could power next-generation "forever" implants—especially for low-demand sensors or as part of a hybrid system that supplements a primary battery.

For a detailed technical survey of biofuel cell design and in vivo results, refer to this review in Energy & Environmental Science.

Hybrid and Integrated Systems

No single energy-harvesting technology can yet guarantee uninterrupted, clinically adequate power for every patient. The future lies in hybrid architectures that combine multiple sources. For example, a pacemaker could draw continuous power from a biofuel cell during rest, supplement with piezoelectric pulses from exercise, and rely on a tiny rechargeable battery for high-demand episodes like pacing spikes or arrhythmia detection. Wireless charging would serve as a backup or periodic top-up. Such redundancy ensures that even if one harvester fails or a source becomes unavailable, the device continues to function.

Advanced energy management integrated circuits (ICs) now exist that can harvest from multiple inputs, store energy in supercapacitors or thin-film lithium batteries, and prioritize loads. Companies like Medtronic and Boston Scientific are investing heavily in these technologies, recognizing that extended device longevity is a key differentiator in a competitive market. A recent Medtronic clinical study reported that their Micra™ leadless pacemaker, while still battery-dependent, has a projected lifespan of 12+ years—but even that could be doubled with adjunct energy harvesting.

Future Outlook and Clinical Translation

The roadmap for long-lasting cardiac implants divides into near-term (5–10 years) and long-term (15+ years) horizons. In the near term, wireless charging will likely be the first to reach broad clinical adoption. Several companies have already received CE Mark approvals for inductive charging systems in pacemakers, with FDA approvals expected within two to three years. These systems will not eliminate batteries entirely but will allow devices to be recharged noninvasively, extending effective lifetime by 50–100%.

Piezoelectric harvesting may follow, especially in younger, more active patients who generate sufficient mechanical motion. Clinical trials pairing piezoelectric patches with standard pacemaker leads are underway, with early data showing no adverse effects on cardiac function. Biofuel cells remain the longest shot, requiring breakthroughs in enzyme stability and power density. However, the convergence of materials science (e.g., flexible, stretchable electronics) and tissue engineering (e.g., vascularizing the implant site) could accelerate progress.

Beyond power, implant longevity also depends on battery capacity and the energy efficiency of the device's electronics. Ultra-low-power microcontrollers and energy-aware pacing algorithms can reduce baseline consumption by 30–40%, synergizing with harvesting technologies. The integration of artificial intelligence for adaptive pacing may further optimize energy use.

Ultimately, the goal is a cardiac implant that lasts the lifetime of the patient—no surgeries for battery replacement, reduced infection risk, and lower cost. While challenges in biocompatibility, regulatory approval, and manufacturing scale remain, the trajectory is clear: the future of cardiac implants is self-powered, wirelessly enabled, and practically immortal.